A Dundee company which pioneers revolutionary, market-leading biotechnology is gearing up to expand its team as it seeks to fulfil ambitious international growth plans.
Cellexus International Ltd (Cellexus) has strengthened its commitment to the city and is poised to recruit at least two additional staff as it expands its corporate horizons into a growing number of overseas markets.
From the company’s research, development and manufacturing base in Dundee, Cellexus provides its CellMaker range of the only single use, purely airlift bioreactor systems on the market to customers across the life sciences sector, including biotech laboratories and academic settings. The patented system is fully customisable to ensure bespoke solutions for customers thus offering a faster route to market than incumbent technologies.
More than a decade of development sits behind the brand which was acquired by its current management in 2017 and is headed by CEO Gavin Hands. Cellexus currently employs a team of eight specialists with that number expected to hit double digits by the end of this year.
With sales now evenly split between UK and overseas markets, recent installations for the flourishing bioreactor manufacturing company have taken its products to the likes of Hungary, Texas and South Korea for the first time. These successes now mean that Cellexus systems are already in place in 11 countries across three continents, and engagement is ongoing with 23 countries through active accounts and enquiries.
Having been named as a finalist in the Small Business and Technology categories of this year’s Courier Business Awards, the company’s global presence is set for imminent further expansion at forthcoming trade events in Barcelona at CPHI and Philadelphia at the World AMR Congress where Cellexus will exhibit for the first time.
Commenting on how the company is gearing up for growth, Gavin Hands said: “We are now having conversations in every European country and looking at new applications where there is growth and scalability such as phage, viral vector, protein and antibody manufacturing.
“In order to help us follow through on these target applications, it is important that we add to our pool of expertise to ensure that we are correctly positioned for what promises to be an exciting phase in our corporate journey.”
